诺诚健华:BCL2抑制剂ICP-248治疗急性髓系白血病获批临床

美港电讯
19 Sep 2024

【诺诚健华:BCL2抑制剂ICP-248治疗急性髓系白血病获批临床】金十数据9月19日讯,诺诚健华今天宣布,公司自主研发的BCL2抑制剂ICP-248联合阿扎胞苷治疗急性髓系白血病(AML)在中国获批临床。BCL2是细胞凋亡通路的重要调控蛋白,其表达异常与多种恶性血液肿瘤的发生发展相关。ICP-248是一款新型口服高选择性BCL2抑制剂,通过选择性地抑制BCL2,恢复肿瘤细胞程序性死亡机制,从而发挥抗肿瘤疗效。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10